- Home
- SEER vs ACRS Comparison
SEER vs ACRS Comparison
Compare SEER & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- ACRS
- Stock Information
- Founded
- SEER 2017
- ACRS 2012
- Country
- SEER United States
- ACRS United States
- Employees
- SEER 134
- ACRS N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- ACRS Health Care
- Exchange
- SEER Nasdaq
- ACRS Nasdaq
- Market Cap
- SEER 121.8M
- ACRS 127.6M
- IPO Year
- SEER 2020
- ACRS 2015
- Fundamental
- Price
- SEER $1.84
- ACRS $1.26
- Analyst Decision
- SEER Hold
- ACRS Strong Buy
- Analyst Count
- SEER 1
- ACRS 7
- Target Price
- SEER $3.00
- ACRS $10.67
- AVG Volume (30 Days)
- SEER 174.6K
- ACRS 801.8K
- Earning Date
- SEER 05-13-2025
- ACRS 05-08-2025
- Dividend Yield
- SEER N/A
- ACRS N/A
- EPS Growth
- SEER N/A
- ACRS N/A
- EPS
- SEER N/A
- ACRS N/A
- Revenue
- SEER $14,170,000.00
- ACRS $17,777,000.00
- Revenue This Year
- SEER $23.54
- ACRS N/A
- Revenue Next Year
- SEER $42.98
- ACRS $425.96
- P/E Ratio
- SEER N/A
- ACRS N/A
- Revenue Growth
- SEER N/A
- ACRS N/A
- 52 Week Low
- SEER $1.56
- ACRS $0.95
- 52 Week High
- SEER $2.63
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- SEER 41.77
- ACRS 43.64
- Support Level
- SEER $1.88
- ACRS $1.20
- Resistance Level
- SEER $1.97
- ACRS $1.46
- Average True Range (ATR)
- SEER 0.10
- ACRS 0.11
- MACD
- SEER -0.02
- ACRS 0.02
- Stochastic Oscillator
- SEER 0.00
- ACRS 41.77
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.